---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-037840"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2026-08-13T20:45:32+00:00"
generated_at: "2026-08-13T20:46:07.140074+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics Q2 2026 net loss narrows to $4.2M; FDA agrees on CLD-401 path

## Summary
- Net loss attributable to common stockholders: $4.2M ($2.94/share) vs $5.7M ($31.75/share) in Q2 2025, adjusted for 1-for-16 reverse split.
- G&A expenses cut 48% to $1.6M from $3.1M; R&D flat at $2.6M.
- Cash and restricted cash $4.3M at June 30, 2026 vs $5.8M at Dec 31, 2025.
- FDA pre-IND feedback for CLD-401 supports first-in-human study; first patient dosing targeted Q1 2027.
- Added Corsee Sanders, Ph.D. (ex-Genentech/Roche, Celgene) to Board.

## SEC filing metadata
- accession: 0001493152-26-037840
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2026-08-13T20:45:32+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315226037840/0001493152-26-037840-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315226037840/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-037840
- JSON: https://secwatch.observer/filing/0001493152-26-037840.json
- Plain text: https://secwatch.observer/filing/0001493152-26-037840.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.